This site is intended only for healthcare professionals resident in the Republic of Ireland
ZAVICEFTA (ceftazidime/avibactam) provides dosing options to treat paediatric patients aged 3 months to <18 years with consistent dosing across indications1
|Age Group||Dose of ceftazidime/ avibactam||Frequency||Infusion time||Duration of treatment|
|6 months to
|50 mg/kg/12.5 mg/kg to a maximum of 2 g/0.5 g||Every 8 hours||2 hours||
cIAI: 5–14 days
cUTI, including pyelonephritis:¶ 5–14 days
HAP/VAP: 7–14 days
LTO: Guided by the severity of the infection, the pathogen(s) and the patient’s clinical and bacteriological progress||
|3 months to <6 months**||40 mg/kg/
|Every 8 hours||2 hours|
Zavicefta® (avibactam sodium, ceftazidime pentahydrate)
Legal Category: S1A
Further information available upon request
Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
Adverse events should also be reported to Pfizer Medical Information on 1800 633 363
Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.
This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie
This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.
Copyright © 2023 Pfizer Limited. All rights reserved.
The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.
I confirm that I am a healthcare professional resident in the Republic of Ireland.*
If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.
PP-UNP-IRL-0176. January 2023